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Edited by Takashi GojoboriAbstract Short hairpin RNAs (shRNAs) have been used to
achieve stable target knockdown in a variety of biological
systems. Here, we report the development of a tightly regulated
tetracycline-responsive human U6 promoter for shRNA expres-
sion. By engineering two copies of the tet operators ﬂanking the
TATA box of the human U6 promoter, we created a U6
promoter derivative (2O2) that exhibited much lower basal
transcriptional activity compared with recently reported induc-
ible pol III dependent promoters. As a consequence of its tighter
regulation, the 2O2 system greatly improved the success rate in
making inducible knockdown cell lines.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Short hairpin RNA; Small interfering RNA;
Tetracycline-responsive; U6 promoter; Tight regulation1. Introduction
The use of small interfering RNA (siRNA) is fast becoming
the method of choice to study gene functions in various bio-
logical systems. The recent development of pol III dependent
short hairpin RNA (shRNA) expression systems further en-
ables stable target knockdown in cells or animals [1–5].
However, the constitutive activity of RNA polymerase III (pol
III) dependent promoters imposes various restrictions on the
application of these expression systems. There have been at-
tempts to develop tetracycline responsive pol III dependent
promoters. Both O1 and O2 types of tetracycline-responsive
derivatives of the human U6 promoter were described in the
literature [6]. Very recently, several groups reported controlled
shRNA expression using the O1 or the O2 type U6 promoters,
or using a human H1 promoter variant with a design similar to
the O2 type U6 promoter [7–9]. Although these systems ap-
peared to be tightly regulated in reported studies, we observed
severe leakiness when we used the O1 or O2 type promoter to
express an shRNA targeting luciferase. It is likely that when a
potent shRNA is used, a slight leakiness of the system could
lead to a signiﬁcant reduction of the target protein.
To overcome the leakiness associated with the current in-
ducible shRNA expression systems, we have developed a* Corresponding author. Fax: +1-847-937-4007.
E-mail address: yu.shen@abbott.com (Y. Shen).
Abbreviations: siRNA, small interfering RNA; shRNA, short hairpin
RNA; pol III, RNA polymerase III; Hif1a, hypoxia inducible factor a;
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transcriptional activity. By engineering two tet operators into
various positions of the human U6 promoter, we demonstrated
that properly placing two O2 type tet operators ﬂanking the
TATA box resulted in a very tightly regulated U6 promoter
variant. We further demonstrated that the tighter regulation of
our expression system greatly improves the success rate in
making inducible knockdown cell lines.2. Materials and methods
2.1. Luciferase assay
Luciferase reporter constructs, pGL-3 (Promega) and pRL-TK
(Promega), were transfected into cells using Lipofectamine 2000 (In-
vitrogen). Luciferase activity was determined using the Dual-Lucifer-
ase Assay System (Promega).
2.2. Western blot analysis
Cells were directly lysed on 6-well plates in 1· Laemmli sample
buﬀer. Proteins were separated by SDS–PAGE, transferred to PVDF
membrane, and Western blotting was performed according to standard
procedures.
2.3. Cell culture
D54-MG cells were grown in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum (FBS). HeLa-TREx cells
(Invitrogen) were grown in minimum essential medium supplemented
with 10% FBS. H1299 cells were grown in RPMI1640 medium sup-
plemented with 10% FBS. All cells were maintained at 37 C in an
environment of 5% CO2.
2.4. Molecular cloning
The human U6 promoter was synthesized by PCR assembling of
overlapping primers.
Tetracycline regulated U6 promoter variants with tet operators at
various positions were all generated by PCR modiﬁcation of the U6
promoter. Plasmids that use U6 promoter variants to express shRNAs
were generated by PCR from respective promoter variants using a 50
primer that hybridizes to the U6 promoter and 30 primers that contain
the hairpin sequences and hybridize to respective promoter variants.
The PCR fragments were then cloned into pBluescript II (SK+).3. Results
3.1. Construction of a tightly regulated human U6 promoter
variant
We ﬁrst investigated whether two tet operators can be
engineered into the U6 promoter without abolishing the
transcriptional activity. An O1 type tet operator was ﬁrst
engineered between the PSE and the TATA box to create a
O1 type U6 promoter that is identical to a previouslyblished by Elsevier B.V. All rights reserved.
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modiﬁed human U6 promoters with two tet operators were
then created by replacing part of the O1 type promoter with
an O2 type tet operator (Fig. 1). The transcriptional activities
of the modiﬁed human U6 promoters were assessed by the
ability of each promoter to express an shRNA targeting lu-
ciferase and inhibit the reporter activity. Based on a dose–
response experiment using U6_luc, which utilizes the wild
type U6 promoter to drive the expression of a luciferase
shRNA, an amount of shRNA plasmid (0.008 lg) that ex-
hibited 80% inhibition of the reporter activity was chosen for
evaluation of the transcriptional activity exhibited by the
modiﬁed U6 promoters. The degree of inhibition varied in
cells transfected with U6 derivatives that contain both the O1
and O2 type tet operators. A similar degree of inhibition on
luciferase activity was observed in cells transfected with
O1_luc, O1O2_luc3, O1O2_luc4, O1O2_luc5, and
O1O2_luc6, suggesting that introducing an additional O2
type tet operator into the O1 type promoter at these positions
has only a marginal eﬀect on the transcriptional activity
(Fig. 2A, O1O2_3, O1O2_4, O1O2_5, and O1O2_6).
The active U6 promoter derivatives were then examined for
their response to doxycycline. Strong inhibition of luciferase
activity was observed in cells transfected with O1_luc,
O1O2_luc5, and O1O2_luc6 regardless of the presence or ab-
sence of doxycycline, suggesting that these promoters are very
leaky under these experimental conditions (Fig. 2B, O1,
O1O2_luc5, and O1O2_luc6). In contrast, cells transfected
with O1O2_luc3 and O1O2_luc4 exhibited much lower lucif-
erase activity in the presence of doxycycline than in the ab-
sence of doxycycline. However, even in the absence of
doxycycline, O1O2_luc3 and O1O2_luc4 transfected cells ex-
hibited a >50% reduction of luciferase activity compared with
cells transfected with a control vector (Fig. 2B, O1O2_3, and
O1O2_4), suggesting that these promoters are still quite leaky
despite of improved regulation compared to the O1 type pro-
moter.Fig. 1. Sequence alignment of U6 promoter variants. U6 is the wild type hum
as previously described, respectively. O1O2_1, O1O2_2, O1O2_3, O1O2_4, O
type tet operators. 2O2 is the U6 promoter variant with two O2 type tet o
operator. The underscored non-italic sequence represents the O1 type tet opTo further improve the inducible system, the O2 type tet
operator was introduced to replace the O1 type tet operator in
O1O2_3 to generate a 2O2 type promoter (Fig. 1, 2O2). Be-
cause the O2 type tet operator has higher binding aﬃnity for
tet repressor (tetR) than the O1 type tet operator [10], it is
likely that tetR will bind more tightly to the 2O2 type pro-
moter than the O1O2_3 type promoter, resulting in reduced
basal transcriptional activity of the promoter. In the absence
of doxycycline, O1O2_luc3 caused >70% reduction of the lu-
ciferase activity as compared with the control plasmid
(Fig. 2C, O1O2). Under the same condition, 2O2_luc caused
no more than 30% inhibition of the luciferase activity (Fig. 2C,
2O2), indicating that the 2O2 promoter indeed has less basal
activity compared with the O1O2_3 promoter. Meanwhile,
O2_luc caused about 85% reduction of the luciferase activity,
suggesting that single O2 type tet operator is also very leaky in
the absence of doxycycline (Fig. 2C, O2). In the presence of
doxycycline, both O1O2_luc3 and 2O2_luc exhibited more
than 80% inhibition of the luciferase activity, suggesting that
the 2O2 and O1O2_3 type promoters have similar activities
upon induction (Fig. 2C). These results demonstrated that it is
possible to engineer two tet operators into the U6 promoter
without dramatically sacriﬁcing the transcriptional activity.
Meanwhile, with two O2 type tet operators ﬂanking the TATA
box, the resulting U6 promoter variant, 2O2, exhibited the best
doxycycline response compared with U6 promoter variants
with a single tet operator (O1 or O2) or a combination of O1
and O2 type tet operators (O1O2).
3.2. Inducible knockdown of endogenous proteins by stably
integrated 2O2 promoter
To determine whether the 2O2 promoter retains the ability
to respond to doxycycline after integrating into chromosomes,
we used a commercial tetR expressing cell line, HeLa-TREx, to
establish stable clones that carried the 2O2 promoter linked to
an shRNA targeting human Hif1a (2O2_Hif1). Among the ﬁve
clones that carried the 2O2_Hif1 cassette, two clones exhibitedan U6 promoter. O1 or O2 is the O1 and O2 type human U6 promoter
1O2_5, and O1O2_6 are U6 promoter variants with both O1 and O2
perators. The underscored italic sequence represents the O2 type tet
erator.
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Fig. 2. Transcriptional activity and tetracycline response of U6 pro-
moter variants. (A) The plasmids that use each U6 promoter variants
to express shRNAs are designated as U6_luc, O1_luc, O1O2_luc1,
O1O2_luc2, O1O2_luc3, O1O2_luc4, O1O2_luc5, and O1O2_luc6.
0.008 lg each of these plasmids or a control vector was cotransfected
with 1 lg pGL3-control and 0.5 lg pRL-TK. Luciferase activities in
transfected cells were determined 72 h post transfection. (B) 0.2 lg
each of a control plasmid, U6_luc, O1_luc, and O1O2_3–6 was con-
transfected with 1 lg pGL3-control, 0.5 lg pRL-TK and 1 lg of
pcDNA6/TR. (C) 0.2 lg each of a control plasmid, U6_luc, O1O2_3,
O1_luc, O2_luc, or 2O2_luc was contransfected with 1 lg pGL3-
control, 0.5 lg pRL-TK and 1 lg of pcDNA6/TR. For doxycycline
treatment, cells were changed to culture medium containing 1 lg/ml of
doxycycline 24 h post transfection. Luciferase activities were deter-
mined 48 h after induction by doxycycline.
Fig. 3. Tetracycline dependent target knockdown in stable cell lines
using the 2O2 expression system. (A) Hela-TREx stable cell lines with
integrated 2O2 vector (vec1, vec2) or 2O2_Hif1(Hif1-6, Hif1-7) were
treated with 1 lg/ml doxycycline for 24 h followed by 6 hour treatment
with 100 lM DFO. (B) Hif1-7 cells were treated with 1 lg/ml of
doxycycline for indicated time before being treated with 100 lM DFO
for 6 h. (C) Hif1-7 cells were treated with diﬀerent concentrations of
doxycycline for 48 h followed by 6 h treatment with 100 lM DFO.
After treatment, cells were lysed and analyzed by Western blotting
using an antibody against Hif1a or Hif1b.
378 X. Lin et al. / FEBS Letters 577 (2004) 376–380a more than 90% reduction of HIF1a protein upon induction
(Fig. 3A, Hif1-6 and Hif1-7). These results demonstrated that
the 2O2 promoter retains its doxycycline responsive property
after integrating into a chromosome.
Using the best-regulated 2O2_Hif1 clone (Hif1-7), we fur-
ther characterized the time and dose dependency of doxycy-
cline induction of the 2O2 expression system. A signiﬁcant
reduction of hypoxia inducible factor a (Hif1a) protein was
observed as early as 12 h after induction and more than 90%
inhibition of Hif-1 protein was observed 24 h after doxycyclinetreatment. Longer induction did not lead to more complete
inhibition of Hif1a protein (Fig. 3B). The doxycycline con-
centration that is required for maximal induction of the 2O2
system was determined in a dose–response experiment. A more
than 90% inhibition of Hif-1 protein was observed in the
presence of 0.1 ng/ml of doxycycline and the maximal inhibi-
tion of Hif1a protein was reached in the presence of 10 ng/ml
of doxycycline (Fig. 3C). These results highlight the fast re-
sponse and extreme sensitivity of the 2O2 system to doxycy-
cline induction.
3.3. Comparison of the O1 and 2O2 systems in making cell lines
During the course of our study, three groups reported pol III
dependent inducible expression systems for regulated target
knockdown [7–9]. In contrast to these reported observations,
we observed severe leakiness of the O1 promoter in our initial
studies (Fig. 2B, O1). To determine whether the observed
leakiness of the O1 system will have a negative impact on the
ability of using the O1 system to create stable cell lines, we
directly compared the success rate of making inducible cell
lines using both the O1 and the 2O2 systems. A D54MG cell
line with high level of tetR expression was ﬁrst established, and
plasmids that utilize the O1 or 2O2 promoters to drive the
expression of shRNAs targeting luciferase (O1_luc and
2O2_luc) were transfected with a hygromycine resistant gene
into this cell line. The drug resistant clones were selected and
analyzed by PCR to identify clones that carry the inducible
shRNA expression cassette. We obtained four clones with
stably integrated O1_luc and seven clones with stably inte-
grated 2O2_luc cassette as analyzed by PCR (data not shown).
All the clones displayed similar level of tetR expression
(Fig. 4B). These clones were examined for their response to
Fig. 4. Comparison of the O1 and 2O2 expression system in making stable cell lines. (A) D54MG-tetR cells with stably integrated O1_luc
(O1_luc1. . .O1_luc4), 2O2_luc (2O2_luc1. . .2O2_luc7) or the 2O2 vector (control) were transfected with 1 lg pGL3-control and 0.5 lg pRL-TK. For
doxycycline treatment, cells were changed into medium containing 1 lg/ml doxycycline 24 h post transfection. Luciferase activities were determined
48 h after induction by doxycycline. (B) The cells in (A) were lysed after treatment with 1 lg/ml doxycycline for 48 h and analyzed by Western
blotting using an anti-tetR antibody. The same blot was stripped and immunoblotted with an anti-actin antibody to show the equal loading of sample
in each lane.
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hibited signiﬁcant doxycycline dependent reduction of lucif-
erase activity (Fig. 4A, O1_luc1 to O1_luc4). Interestingly,
three out of the four O1_luc clones exhibited constitutive in-
hibition of the luciferase activity regardless of the presence or
absence of doxycycline, indicating severe leakiness of the O1
system (Fig. 4A, O1_luc1, O1_luc2, and O1_luc4). In contrast,
among the seven 2O2_luc clones, two clones exhibited strong
doxycycline dependent inhibition of luciferase activity
(Fig. 4A, 2O2_luc2, 2O2_luc4) and three clones displayed
modest degree of doxycycline dependent inhibition of lucifer-
ase activity (Fig. 4A, 2O2_luc1, 2O2_luc5, and 2O2_luc7). The
shRNA expression cassette for clones O1_3, 2O2_3 and 2O2_6
could be inserted into transcriptional inactive site in a chro-
mosome, resulting in no inhibition of luciferase activity re-
gardless of the presence or absence of doxycycline.4. Discussion
We have developed a tightly regulated tetracycline respon-
sive U6 promoter for expressing shRNA. Although the origi-
nally described O1 system was successfully used for inhibition
of DNMT in a tetracycline-dependent manner [6], the O1
system was extremely leaky when used to express shRNA
targeting luciferase both in transient assays and in stable celllines. There are multiple factors that could contribute to these
diﬀerent observations. For example, it is well known that
diﬀerent siRNAs function at vastly diﬀerent concentrations.
For potent siRNAs, a 90% knockdown of targets can be
achieved by transfecting sub-nanomolar amounts of siRNA;
while for others, 100 nM may be required to achieve the same
degree of target knockdown. This diﬀerence in functional
concentration of siRNA could result in a diﬀerent tolerance of
leakiness of the shRNA expression system. For less potent
siRNAs, slight leakiness of the system will not generate a
dramatic eﬀect on the target protein level. However, for potent
siRNAs such as the luciferase shRNA used in our study, a
slight leakiness of the system will produce enough siRNA to
signiﬁcantly knockdown the target.
Another factor that will aﬀect the regulation of the O1
system is the tetR expression level. In our experience, although
the O1 system appeared to be constitutively active when the
O1_luc and a plasmid for tetR expression were transfected at a
1:5 ratio, the system did exhibit a small degree of tetracycline
responsiveness when the two plasmids were transfected at
about a 1:300 ratio (data not shown). The tetR expression cell
line that was used to demonstrate inducible knockdown of
DNMT might express an extremely high level of tetR, because
the induced target knockdown is only apparent when 10 lg/ml
of doxycycline was used as compared to 0.1 ng/ml of doxy-
cycline in our study. The requirement for high tetR expression
380 X. Lin et al. / FEBS Letters 577 (2004) 376–380level could limit the use of the inducible system in several ways.
First, a signiﬁcant amount of eﬀort will need to be spent on
identifying tetR expressing cell lines or tetR expressing mice
with a high enough level of tetR expression for complete in-
hibition of the basal activity of the O1 system. Second, the high
dose of doxycycline required to induce the shRNA expression
might generate undesired side eﬀects. This is especially prob-
lematic if the inducible system is used in vivo.
Two other regulated pol III dependent promoters with de-
signs similar to the O2 type U6 promoter have also been used
to express shRNA [7,9]. Although we did not compare O2
system directly to 2O2 system in making stable cell lines, we
did observe severe leakiness of O2 systems in transient assays
(Fig. 2C). The direct comparison of 2O2 system with the in-
ducible H1 promoter is diﬃcult because the optimal shRNA
sequence that can be used in the H1 promoter system and the
U6 promoter system is diﬀerent. Because the inducible H1
promoter is similar in design to the O2 type U6 promoter, it is
likely that the regulation of the two systems is similar.
Although it is possible to obtain an inducible knockdown of
targets in cell lines or in animals using a single tet operator
inducible system, provided a shRNA with proper potency is
used and suﬃcient number of clones are screened, using a
much tightly regulated two tet operator system such as the 2O2
system could markedly improve the success rate in generating
stable cell lines. The high success rate is particularly importantfor making inducible knockdown mice, because of the diﬃ-
culty and high cost associated with screening for large number
of ES clones or founder mice for desired regulation of targets.
The ease of generating stable cell lines using 2O2 coupled with
the prompt response to very low dose of doxycycline, etc.,
makes it a useful system for studying loss of function pheno-
type in cell lines and in animals or applying RNAi to gene
therapy.
References
[1] Brummelkamp, T.R., Bernards, R. and Agami, R. (2002) Science
296, 550–553.
[2] Miyagishi, M. and Taira, K. (2002) Nat. Biotechnol. 20,
497–500.
[3] Paddison, P.J., Caudy, A.A., Bernstein, E., Hannon, G.J. and
Conklin, D.S. (2002) Genes Dev. 16, 948–958.
[4] Paul, C.P., Good, P.D., Winer, I. and Engelke, D.R. (2002) Nat.
Biotechnol. 20, 505–508.
[5] Sui, G., Soohoo, C., Aﬀar el, B., Gay, F., Shi, Y. and Forrester,
W.C. (2002) Proc. Natl. Acad. Sci. USA 99, 5515–5520.
[6] Ohkawa, J. and Taira, K. (2000) Hum. Gene Ther. 11,
577–585.
[7] van de Wetering, M. et al. (2003) EMBO Rep. 4, 609–615.
[8] Matsukura, S., Jones, P.A. and Takai, D. (2003) Nucleic Acids
Res. 31, e77.
[9] Czauderna, F. et al. (2003) Nucleic Acids Res. 31, e127.
[10] Hillen, W. and Berens, C. (1994) Annu. Rev. Microbiol. 48,
345–369.
